Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
GLP-1 agonists are not a substitute for insulin
Lifestyle changes are foundational and synergistic, yet many patients will still benefit from pharmacologic support, including GLP1 therapies, for meaningful MASH improvement
That was a nonnegotiable. Now its not a necessity anymore. This report was first published by Stateline, part of the States Newsroom nonprofit news network supported by grants and a coalition of donors as a 501c(3) public charity
Untreated Controls Preclinical injury models % reduction in healing time Tendon Transection (Rat Achilles model)50% Skin Wound Closure (Alkali burn model)45% Muscle Crush Injury (Rat quadriceps)40% Safety Data Safety Profile from Research What preclinical and early clinical studies report Preclinical Safety Summary LD50Not achieved Acute toxicityNone observed Chronic toxicityNone in 6-month studies Organ toxicityNone detected Human IV pilot (n=2)No adverse effects Cardiac/hepatic/renalNo effects detected Regulatory & Risk Considerations FDA statusUnapproved drug WADA statusBanned since 2022 (S0) Human trialsPhase 1 only Long-term effectsUnknown in humans Pro-angiogenic riskTheoretical unstudied Australia/NZPrescription only No lethal dose was reached in preclinical toxicology studies
PlexusDx's Precision Peptide Genetic Test examines GIPR variants along with FTO and MC4R pathways to identify your genetic predispositions across 14 metabolic pathways and 150+ insights
US$ 22.70
US$ 23.53
US$ 21.47
US$ 28.04
US$ 26.22
US$ 24.47
